Drug Profile
SB 061
Alternative Names: SB-061Latest Information Update: 11 Jul 2023
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Nordic Bioscience; Symic Bio
- Class Antirheumatics; Drug conjugates; Proteoglycans
- Mechanism of Action Cartilage replacements; Proteoglycan replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 31 May 2023 Efficacy and adverse event data from a phase IIb trial in Osteoarthritis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 25 Jul 2022 No development reported - Phase-II for Osteoarthritis in Denmark (Intra-articular)
- 21 Jan 2020 Phase-II clinical trials in Osteoarthritis in Denmark (Intra-articular) (EudraCT2019-004515-31)